Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: A 52-week multicenter placebo-controlled double-blind parallel group study

Diabetes Care

Volumn 24, Issue 10, 2001, Pages 1776-1782

  Hotta, Nigishi ^a   Toyota, Takayoshi ^b   Matsuoka, Kempei ^c   Shigeta, Yukio ^d   Kikkawa, Ryuichi ^d   Kaneko, Toshio ^e   Takahashi, Akira ^f   Sugimura, Kimiya ^g   Koike, Yasuo ^g   Ishii, Jun ^h   Sakamoto, Nobuo ⁱ  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAISEIKAI CENTRAL HOSPITAL   (Japan)

^d SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^e YAMAGUCHI ROSAI HOSPITAL   (Japan)

^f Tokai Central Hospital of Japan Mutual Aid Association of Public School Teachers   (Japan)

^g NAGOYA UNIVERSITY   (Japan)

^h SAITAMA MEDICAL UNIVERSITY   (Japan)

ⁱ CHUBU ROSAI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; ENZYME INHIBITOR; FIDARESTAT; GLYCOSYLATED HEMOGLOBIN; IMIDAZOLE DERIVATIVE; IMIDAZOLIDINE DERIVATIVE; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; ELECTROPHYSIOLOGY; FEMALE; HUMAN; HYPESTHESIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PARESTHESIA; PATHOPHYSIOLOGY;

ALDEHYDE REDUCTASE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; ELECTROPHYSIOLOGY; ENZYME INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPESTHESIA; IMIDAZOLES; IMIDAZOLIDINES; MALE; MIDDLE AGED; PAIN; PARESTHESIA; PLACEBOS;

EID: 0035486938     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.24.10.1776     Document Type: Article

References (11)

1. Pfeifer MA, Ross DR, Schrage JP, Gelber DA, Schumer MP, Crain GM, Markwell SJ, Jung S: A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy. Diabetes Care 16:1103-1115, 1993
2. Asbury AK, Fields HL: Pain due to peripheral nerve damage: an hypothesis. Neurology 34:1587-1590, 1984
3. Portenoy RK: Painful polyneuropathy. Neurol Clin 7:265-288, 1989
4. Hotta N: New approaches for treatment in diabetes: aldose reductase inhibitors. Biomed Phamacother 49:232-243, 1995
5. Mizuno K, Yamaguchi T, Inoue A, Tomiya N, Unno R, Miura K, Usui T, Matsumoto Y, Kondo Y, Yoshina S, Kondo Y, Sato M, Matsubara A, Kato N, Nakano K, Shirai M, Inoue T, Awaya J, Asaeda N, Hayasaka I, Koide M, Hibi C, Ban M, Sawai K, Kurono M: Profile of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2′-5′-dioxospiro[chroman-4,4′-imidazolizine]-2- carboxamide. In Current Concepts of Aldose Reductase and Its Inhibitions. Sakamoto N, Kinoshita JH, Kador PF, Hotta N, Eds. Amsterdam, Elsevier, 1990, p. 89-96
6. Mizuno K, Kato N, Matsubara A, Nakano K, Kurono M: Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2′, 5′-dioxospiro[chroman-4,4′-imidazolizine]-2-carboxamide (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats. Metabolism 41:1081-1086, 1992
7. Yamaguchi T, Miura K, Usui T, Unno R, Matsumoto Y, Fukushima M, Mizuno K, Kondo Y, Baba Y, Kurono M: Synthesis and aldose reductase inhibitory activity of 2-substituted-6-fluoro-2,3-dihydrospiro [4H-1-benzopyran-4,4′-imidazolidine] -2′, 5′-diones. Arzneimittelforschung 44:344-348, 1994
8. Hotta. N, Koh N, Sakakibara F, Nakamura J, Hamada Y, Naruse K, Sasaki H, Mizuno K, Matsubara A, Kakuta H, Fukasawa H, Sakamoto N: Effect of an aldose reductase inhibitor, SNK-860, on deficit in the electroretinogram of diabetic rats. Exp Physiol 80:981-989, 1995
9. Mizuno K, Kato N, Makino M, Suzuki T, Shindo M: Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy. J Diabetes Complications 13:141-150, 1999
10. Oka M, Matsumoto Y, Sugiyama S, Tsuruta N, Matsushima M: A potent aldose reductase inhibitor, (2S, 4S)-6-fluoro-2′, 5′-dioxospiro[chroman-4,4′-imidazolidine]-2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography. J Med Chem 43:2479-2483, 2000
11. Kato N, Mizuno K, Makino M, Suzuki T, Yagihashi S: Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats. Diabetes Res Clin Pract 50:77-85, 2000